Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
3
×
clinical trials
europe blog main
3
×
europe top stories
fda
3
×
life sciences
national blog main
boston blog main
boston top stories
eli lilly
europe
indiana blog main
indiana top stories
national top stories
new york blog main
new york top stories
abbvie
alkermes
allergan
arena pharmaceuticals
boehringer ingelheim
boulder/denver blog main
boulder/denver top stories
buprenorphine
cancer
cardiovascular disease
cariprazine
colorectal cancer
detroit blog main
detroit top stories
eisai
empagliflozin
felipe jain
jess fiedorowicz
jessica jeffrey
karim calis
lorcaserin
lumateperone
lung cancer
m health fairview
What
drug
3
×
fda
3
×
medicine
patients
weight
alkermes
antipsychotic
approval
benefits
bid
boehringer
cancer
caveats
commonly
designed
diabetes
effect
eisai
eli
expand
fallen
favor
flags
gain
higher
incidence
ingelheim
lilly
lorcaserin
loss
market
marketed
marketing
medicine’s
offer
panel
post
prescribed
psyche
pulls
Language
unset
3
×
Current search:
drug
×
biotech
×
unset
×
fda
×
" europe blog main "
×
fda
×
@xconomy.com
3 years ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks